Race, Socioeconomic Status, and Survival: A Pathway Analysis in Metastatic Non-Small-Cell Lung Cancer

Lung cancer remains the leading cause of cancer death in the United States, claiming more lives than colon, breast, and prostate cancers combined. For the vast majority of these cases, the disease is a type known as non-small cell lung cancer. Tragically, nearly half of these patients are not diagnosed until the cancer has spread to other parts of the body, a stage where survival rates are historically very low. While the disease affects people of all backgrounds, a stark and persistent gap exists in who survives and who does not. Black patients with advanced lung cancer face significantly lower survival rates compared to their White counterparts. For decades, researchers have sought to understand the root of this disparity. Is it a matter of biology, or is it something deeper, woven into the social and economic fabric of daily life? The prevailing view in modern public health suggests that race is not a biological trait but a social construct, shaped by systemic inequities that determine where people live, how they access care, and what health challenges they face before they even enter a hospital.

A team of researchers at the University of Minnesota set out to trace the exact path that leads from race to survival in patients with metastatic non-small cell lung cancer. They wanted to see if the gap in survival was caused by the patients themselves or by the circumstances surrounding them. To do this, they looked at a massive collection of medical records from over 8,500 patients aged 65 and older, spanning the years 2016 through 2019. This data linked cancer registry information with Medicare claims, allowing the researchers to see not just the diagnosis, but the patient's neighborhood, their history of other health problems, the stage of the cancer when found, and whether they received life-saving treatment. The researchers focused specifically on Black and White patients to map out a chain of events, starting with where a patient lives and ending with whether they survived.

The study began by examining the neighborhoods where these patients lived. The researchers used a measure of neighborhood socioeconomic status, which combines factors like income, education, and employment rates in a specific area. They found a clear pattern: Black patients were far more likely to live in neighborhoods with lower socioeconomic status compared to White patients. In fact, nearly half of the Black patients in the study lived in low-income neighborhoods, whereas only about one in six White patients did. This difference in neighborhood conditions was not just a background detail; it was the first domino in a long line of consequences. Living in a neighborhood with fewer resources was strongly linked to having a higher burden of other health problems, such as heart disease or diabetes, before the cancer diagnosis even occurred.

As the researchers followed the chain of events, they discovered that these pre-existing health problems and the conditions of the neighborhood influenced how the cancer presented itself. Patients living in poorer neighborhoods were more likely to have more complex health issues and were diagnosed at a later, more advanced stage of the disease. However, when the researchers adjusted for these factors, the direct link between being Black and having a later-stage diagnosis disappeared. This suggested that the delay in diagnosis was not due to race itself, but rather to the socioeconomic disadvantages that often accompany it. The structural barriers of living in a deprived neighborhood—such as limited access to primary care, financial struggles, and fewer local hospitals—appeared to be the true drivers of late detection.

The most critical turning point in the study was the decision to treat the cancer. The researchers found that receiving systemic treatment, which includes chemotherapy and immunotherapy, was the single most powerful factor in determining whether a patient lived or died. Patients who did not receive this treatment were nearly four times more likely to die than those who did. Yet, a significant number of Black patients did not receive treatment. When the team analyzed why, they found that race was not the independent reason for this gap. Instead, the decision not to treat was driven by the same factors that had appeared earlier in the chain: living in a low socioeconomic neighborhood and having a high burden of other health conditions. Patients who were older, sicker, or living in deprived areas were much less likely to be offered or able to undergo treatment, often because their doctors deemed them too frail to withstand the rigors of therapy.

When the researchers finally put all these pieces together in a single model, the picture became clear. The survival gap between Black and White patients, which looked so large at the beginning, vanished once the researchers accounted for neighborhood conditions, the complexity of the patient's health at diagnosis, and whether they received treatment. In the final analysis, being Black did not independently predict a higher risk of death. Instead, the risk was carried by the circumstances of the patient's life. The disparity was not a biological inevitability but a result of a sequential pathway where structural inequalities led to poorer health at diagnosis, which in turn led to a lack of treatment, and finally, to reduced survival.

The study concludes that the path to health equity for Black patients with lung cancer lies in addressing these upstream factors. It is not enough to simply offer treatment; the barriers that prevent patients from reaching that treatment must be dismantled. This means improving access to healthcare in underserved neighborhoods, managing other chronic diseases before they complicate cancer care, and ensuring that patients with complex health needs are not automatically excluded from life-saving therapies. The researchers emphasize that while race itself cannot be changed, the effects of racism and the resulting socioeconomic deprivation can be. By focusing on the social and economic conditions that shape a patient's journey, the medical community can begin to close the gap in survival, ensuring that the outcome of a lung cancer diagnosis depends on the quality of care received, not the color of the patient's skin.